Melatonin Glenmark

Melatonin, the active ingredient in Melatonin Glenmark, is a melatonin receptor agonist presented as an oral product for oral use. It helps regulate the circadian rhythm and is used to support sleep in adults.

GNH USA supplies Melatonin Glenmark as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melatonin acts on the melatonin receptor pathway to address sleep‑wake rhythm disorders.

- Insomnia (adult): helps reduce sleep onset latency and improve overall sleep quality. - Jet lag (travelers): assists the body in adjusting its internal clock after crossing time zones. - Shift work disorder (shift workers): supports alignment of sleep timing with irregular work schedules.

Melatonin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Drowsiness or daytime sleepiness - Headache - Dizziness - Nausea or mild gastrointestinal discomfort - Vivid dreams or nightmares - Mild fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, itching or anaphylaxis - Mood changes including depression or agitation - Seizures (rare) - Severe hypotension or cardiovascular effects - Hepatic enzyme alterations (rare) - Persistent tachycardia

When using Melatonin Glenmark, consider the following safety measures.

- Pregnancy: safety not established; consult a healthcare professional before use. - Breastfeeding: limited data; use with caution and professional guidance. - Concomitant CNS depressants: may increase sedation; monitor patient response. - Elderly patients: start with the lowest effective dose to reduce risk of excessive drowsiness. - Patients with autoimmune disorders: monitor for potential disease activity changes. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Melatonin can interact with several medication classes; awareness of the interaction level is important.

Major Interactions (Avoid): - Warfarin (anticoagulant): may increase bleeding risk. - Cyclosporine (immunosuppressant): may reduce immunosuppressive efficacy. - Fluoxetine or other CYP1A2 inhibitors: can raise melatonin plasma concentrations.

Moderate Interactions (Monitor Closely): - Benzodiazepines or other CNS depressants: additive sedative effect. - Antihypertensive agents: potential enhancement of blood pressure lowering. - Oral contraceptives: may increase circulating melatonin levels.